BACKGROUND: Caveolin-1 is a protein that displays promotive versus preventive roles in cancer progression according to circumstances. Temozolomide (TMZ) is the standard chemotherapeutic to treat glioma patients. The present work aims to characterizeTMZ-induced effects on caveolin-1 expression in glioma cells. METHODS: Human astroglioma (U373 and T98G) and oligodendroglioma (Hs683) cell lines were used in vitro as well as in vivo orthotopic xenografts (Hs683 and U373) into the brains of immunocompromisedmice. In vitro TMZ-induced effects on protein expression and cellular localization were determined by Western blot analysis and on the actin cytoskeleton organization by means of immunofluorescence approaches. In vivo TMZ-induced effects in caveolin-1 expression in human glioma xenografts were monitored by means of immunohistochemistry. RESULTS: TMZ modified caveolin-1 expression and localization in vitro and in vivo after an administration schedule that slightly, if at all, impaired cell growth characteristics in vitro. Caveolin-1 by itself (at a 100-ng/ml concentration) was able to significantly reduce invasiveness (Boyden chambers) of the three human glioma cell lines. The TMZ-inducedmodification in caveolin-1 expression in flotation/raft compartments was paralleled by altered Cyr61 and β(1) integrin expression, two elements that have already been reported to collaborate with caveolin-1 in regulating glioma cell biology, and all these features led to profound reorganization of the actin cytoskeleton. An experimental Src kinase inhibitor, AZD0530, almost completely antagonized the TMZ-induced modulation in caveolin-1 expression. CONCLUSION: TMZ modifies caveolin-1 expression in vitro and in vivo in glioma cells, a feature that directly affects glioma cell migration properties.
BACKGROUND:Caveolin-1 is a protein that displays promotive versus preventive roles in cancer progression according to circumstances. Temozolomide (TMZ) is the standard chemotherapeutic to treat gliomapatients. The present work aims to characterizeTMZ-induced effects on caveolin-1 expression in glioma cells. METHODS:Humanastroglioma (U373 and T98G) and oligodendroglioma (Hs683) cell lines were used in vitro as well as in vivo orthotopic xenografts (Hs683 and U373) into the brains of immunocompromisedmice. In vitro TMZ-induced effects on protein expression and cellular localization were determined by Western blot analysis and on the actin cytoskeleton organization by means of immunofluorescence approaches. In vivo TMZ-induced effects in caveolin-1 expression in humanglioma xenografts were monitored by means of immunohistochemistry. RESULTS:TMZ modified caveolin-1 expression and localization in vitro and in vivo after an administration schedule that slightly, if at all, impaired cell growth characteristics in vitro. Caveolin-1 by itself (at a 100-ng/ml concentration) was able to significantly reduce invasiveness (Boyden chambers) of the three humanglioma cell lines. The TMZ-inducedmodification in caveolin-1 expression in flotation/raft compartments was paralleled by altered Cyr61 and β(1) integrin expression, two elements that have already been reported to collaborate with caveolin-1 in regulating glioma cell biology, and all these features led to profound reorganization of the actin cytoskeleton. An experimental Src kinase inhibitor, AZD0530, almost completely antagonized the TMZ-induced modulation in caveolin-1 expression. CONCLUSION:TMZ modifies caveolin-1 expression in vitro and in vivo in glioma cells, a feature that directly affects glioma cell migration properties.
Authors: Benjamin Le Calvé; Michal Rynkowski; Marie Le Mercier; Céline Bruyère; Caroline Lonez; Thierry Gras; Benjamin Haibe-Kains; Gianluca Bontempi; Christine Decaestecker; Jean-Marie Ruysschaert; Robert Kiss; Florence Lefranc Journal: Neoplasia Date: 2010-09 Impact factor: 5.715
Authors: C Decaestecker; I Camby; L Gordower; O Dewitte; P Cras; J J Martin; J L Pasteels; P Van Ham; J Brotchi; R Kiss; I Salmon Journal: J Neuropathol Exp Neurol Date: 1998-08 Impact factor: 3.685
Authors: Balasubramanian Sivasankaran; Martin Degen; Anthony Ghaffari; Monika E Hegi; Marie-France Hamou; Mihai-Constantin S Ionescu; Christian Zweifel; Markus Tolnay; Morten Wasner; Susanne Mergenthaler; André R Miserez; Robert Kiss; Maddalena M Lino; Adrian Merlo; Ruth Chiquet-Ehrismann; Jean-Louis Boulay Journal: Cancer Res Date: 2009-01-15 Impact factor: 12.701
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: Murat Cokakli; Esra Erdal; Deniz Nart; Funda Yilmaz; Ozgul Sagol; Murat Kilic; Sedat Karademir; Nese Atabey Journal: BMC Cancer Date: 2009-02-24 Impact factor: 4.430
Authors: Alexander T Faje; Lisa Nachtigall; Deborah Wexler; Karen K Miller; Anne Klibanski; Hideo Makimura Journal: J Clin Endocrinol Metab Date: 2013-08-08 Impact factor: 5.958
Authors: Xianhui Wang; Jason Wong; Christopher J Sevinsky; Leila Kokabee; Faiza Khan; Yan Sun; Douglas S Conklin Journal: Mol Cancer Ther Date: 2016-06-02 Impact factor: 6.261
Authors: Kevin Quann; Donna M Gonzales; Isabelle Mercier; Chenguang Wang; Federica Sotgia; Richard G Pestell; Michael P Lisanti; Jean-François Jasmin Journal: Cell Cycle Date: 2013-04-17 Impact factor: 4.534
Authors: William H Hicks; Cylaina E Bird; Jeffrey I Traylor; Diana D Shi; Tarek Y El Ahmadieh; Timothy E Richardson; Samuel K McBrayer; Kalil G Abdullah Journal: Cells Date: 2021-03-23 Impact factor: 6.600